8-K: Vicarious Surgical Reports Progress on Version 1.0 System and Sets 2025 Cash Burn Guidance

Vicarious Surgical announces completion of Version 1.0 system integration, progress towards first clinical use, and provides 2025 cash burn guidance of $50 million.

Summary

• Vicarious Surgical announced its fourth quarter and full year 2024 financial results.
• The company finalized the integration of its Version 1.0 system and is progressing towards first clinical use.
• Strategic hospital partnerships were expanded with LSU Health New Orleans, Temple Health, and University of Illinois Health.
• The company's cash burn for 2024 was $49.1 million, in line with guidance.
• Vicarious Surgical has issued full year 2025 cash burn guidance of approximately $50 million.
• Operating expenses for the fourth quarter of 2024 were $15.0 million, a 3% decrease compared to $15.5 million in the prior year period.
• R&D expenses for the fourth quarter of 2024 were $8.5 million, consistent with the fourth quarter of 2023.
• General and administrative expenses for the fourth quarter of 2024 were $5.5 million, compared to $5.9 million in the fourth quarter of 2023.
• Sales and marketing expenses for the fourth quarter of 2024 were $1.0 million, compared to $1.2 million in the fourth quarter of 2023.
• The adjusted net loss for the fourth quarter was $14.4 million, or $2.43 per share, compared to $14.6 million, or $2.50 per share, for the same period last year.
• The GAAP net loss for the fourth quarter was $13.9 million, or $2.36 per share, compared to $13.1 million, or $2.25 per share, for the same period last year.
• Operating expenses for the full year of 2024 were $66.6 million, a 17% decrease compared to $80.7 million in the prior year period.
• R&D expenses for the full year of 2024 were $40.2 million, compared to $47.6 million in the full year of 2023.
• General and administrative expenses for the full year of 2024 were $21.9 million, compared to $26.9 million in the full year of 2023.
• Sales and marketing expenses for the full year of 2024 were $4.5 million, compared to $6.2 million in the full year of 2023.
• The adjusted net loss for the full year of 2024 was $63.3 million, or $10.75 per share, compared to $76.3 million, or $15.67 per share, for the same period last year.
• The GAAP net loss for the full year of 2024 was $63.2 million, or $10.74 per share, compared to $71.1 million, or $14.60 per share, for the same period last year.
• The company had $49.1 million in cash and investments as of December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has achieved key milestones, such as completing the Version 1.0 system integration and expanding hospital partnerships. However, it is still operating at a loss and has a significant cash burn.

Positives

• The company successfully completed the integration of its Version 1.0 system.
• Strategic hospital partnerships have been expanded.
• The company is progressing towards first clinical use.
• Operating expenses decreased by 17% for the full year 2024 compared to 2023.
• R&D, General & Administrative, and Sales & Marketing expenses all decreased for the full year 2024 compared to 2023.
• Adjusted net loss decreased for both the fourth quarter and full year 2024 compared to 2023.
• Cash burn was in line with guidance for 2024.

Negatives

• The company continues to experience net losses.
• The company's cash and investments decreased from $100.953 million in 2023 to $51.698 million in 2024.

Risks

• The company's actual results may differ from its expectations, estimates, and projections.
• The company's ability to raise financing in the future is uncertain.
• The success, cost and timing of the company's product and service development activities are subject to risks and uncertainties.
• The company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System is not guaranteed.
• Economic downturns, political and market conditions could adversely affect the company's business, financial condition and results of operations.
• The company's intellectual property rights may not be adequately protected or enforced.

Future Outlook

Vicarious Surgical expects a full year 2025 cash burn of approximately $50 million and is focused on preparing for first clinical patients later in 2025.

Management Comments

• Adam Sachs, Co-Founder and Chief Executive Officer, stated that 2024 was a pivotal year of progress, with the completion of the Version 1.0 System integration and expansion of strategic hospital partnerships.
• Adam Sachs mentioned that the company's focus is on preparing for first clinical patients later in 2025.

Industry Context

Vicarious Surgical is operating in the competitive robotic surgery market, aiming to improve surgical efficiency, patient outcomes, and reduce healthcare costs. The company's progress with its Version 1.0 system and strategic partnerships positions it to potentially compete with established players like Intuitive Surgical.

Comparison to Industry Standards

• Intuitive Surgical, the maker of the da Vinci surgical system, is the dominant player in the robotic surgery market.
• Globally, the robotic surgery market is expected to grow significantly in the coming years, driven by technological advancements and increasing demand for minimally invasive procedures.
• Vicarious Surgical's focus on human-like surgical robots and virtual transportation of surgeons inside the patient represents a unique approach compared to existing robotic surgery systems.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's progress and financial stability affect employee morale and job security.
• Customers (Hospitals and Surgeons): The development of the Vicarious Surgical System could improve surgical procedures and patient outcomes.
• Patients: Successful implementation of the technology could lead to less invasive surgeries and improved recovery times.

Next Steps

• The company will continue building inventory to support essential performance and safety testing.
• The company will continue securing Institutional Ethics Committee site approvals.
• The company anticipates demonstrating the value of the Vicarious Surgical System in a live clinical setting later in 2025.

Key Dates